

*primary studies - published, non RCT*

## **Safety, Efficacy, and Tolerability of Tezacaftor/Ivacaftor in Cystic Fibrosis Patients Who Previously Discontinued Lumacaftor/Ivacaftor Due To Respiratory Adverse Events: a Randomized, Double-Blind, Placebo-Controlled Phase 3b Study**

**Code:** CN-XXXXX011    **Year:** 2019    **Date:** 1977

**Author:** Schwarz C

### **See also**

Pneumologie (Stuttgart, Germany), 2019, 73(SUPPL. 1)

### **Keywords**

Airway clearance technique; Drainage; Inhalation OR nebulised; non pharmacological intervention - devices OR physiotherapy;